A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy

Choe, Jung-Yoon ; Prodanovic, Nenad ; Niebrzydowski, Jaroslaw ; Staykov, Ivan ; Dokoupilova, Eva ; Baranauskaite, Asta ; Yatsyshyn, Roman ; Mekic, Mevludin ; Porawska, Wieskawa ; Ciferska, Hana ; Jedrychowicz-Rosiak, Krystyna ; Zielinska, Agnieszka ; Choi, Jasmine ; Rho, Young Hee ; Smolen, Josef S

Annals of the rheumatic diseases, 2017-01, Vol.76 (1), p.58-64 [Periódico revisado por pares]

England: BMJ Publishing Group LTD

Texto completo disponível